Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937247 | 0.85 | GPR119 (0.53) | GPR119CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9936121 | 0.84 | GPR119 (0.47) | GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL2593075 | 0.81 | GPR119 (0.50) | GPR119NAMPTPTPN2PTPN1PTPN6 | |
| SCHEMBL9936603 | 0.80 | CHRM2 (0.50) | GPR119NAMPTCHRM2CHRM4CHRM5 | |
| SCHEMBL14575286 | 0.78 | GPR119 (0.48) | GPR119ALDH1A1 | |
| SCHEMBL9936936 | 0.78 | GPR119 (0.48) | GPR119ALDH1A1 | |
| SCHEMBL14575713 | 0.78 | GPR119 (0.48) | GPR119ALDH1A1 | |
| SCHEMBL9935783 | 0.78 | GPR119 (0.48) | GPR119KDM4E | |
| SCHEMBL9936940 | 0.78 | USP30 (0.49) | GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL15007481 | 0.78 | GPR119 (0.58) | GPR119PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | GPR119 1/4885NAMPT 1881/4885CHRM2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.